177 related articles for article (PubMed ID: 26962828)
1. Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.
Porcel JM; Esquerda A; Martínez-Alonso M; Bielsa S; Salud A
Medicine (Baltimore); 2016 Mar; 95(10):e3044. PubMed ID: 26962828
[TBL] [Abstract][Full Text] [Related]
2. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
Wang XF; Wu YH; Wang MS; Wang YS
Asian Pac J Cancer Prev; 2014; 15(1):363-8. PubMed ID: 24528057
[TBL] [Abstract][Full Text] [Related]
3. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
Loveland P; Christie M; Hammerschlag G; Irving L; Steinfort D
Intern Med J; 2018 Nov; 48(11):1318-1324. PubMed ID: 29869427
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
6. [Contribution of pleural fluid analysis to the diagnosis of pleural effusion].
Ferreiro L; Toubes ME; Valdés L
Med Clin (Barc); 2015 Aug; 145(4):171-7. PubMed ID: 25433793
[TBL] [Abstract][Full Text] [Related]
7. Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study.
Choi H; Ko Y; Lee CY
BMC Cancer; 2020 Aug; 20(1):825. PubMed ID: 32867726
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of two strategies for the interpretation of tumour markers in pleural effusions.
Trapé J; Sant F; Franquesa J; Montesinos J; Arnau A; Sala M; Bernadich O; Martín E; Perich D; Pérez C; Lopez J; Ros S; Esteve E; Pérez R; Aligué J; Gurt G; Catot S; Domenech M; Bosch J; Badal JM; Bonet M; Molina R; Ordeig J
Respir Res; 2017 May; 18(1):103. PubMed ID: 28545517
[TBL] [Abstract][Full Text] [Related]
9. Predicting malignant and tuberculous pleural effusions through demographics and pleural fluid analysis of patients.
Valdés L; San-José E; Ferreiro L; Golpe A; González-Barcala FJ; Toubes ME; Rodríguez-Álvarez MX; Álvarez-Dobaño JM; Rodríguez-Núñez N; Rábade C; Gude F
Clin Respir J; 2015 Apr; 9(2):203-13. PubMed ID: 25849297
[TBL] [Abstract][Full Text] [Related]
10. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion.
Lee SH; Lee EJ; Min KH; Hur GY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Lee SY
Clin Biochem; 2013 Oct; 46(15):1484-8. PubMed ID: 23570862
[TBL] [Abstract][Full Text] [Related]
11. Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.
Herrera Lara S; Fernández-Fabrellas E; Juan Samper G; Marco Buades J; Andreu Lapiedra R; Pinilla Moreno A; Morales Suárez-Varela M
Lung; 2017 Oct; 195(5):653-660. PubMed ID: 28656381
[TBL] [Abstract][Full Text] [Related]
12. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
[TBL] [Abstract][Full Text] [Related]
13. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
Creaney J; Segal A; Olsen N; Dick IM; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2014; 2014():413946. PubMed ID: 25505814
[TBL] [Abstract][Full Text] [Related]
14. Investigating unilateral pleural effusions: the role of cytology.
Arnold DT; De Fonseka D; Perry S; Morley A; Harvey JE; Medford A; Brett M; Maskell NA
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30262573
[TBL] [Abstract][Full Text] [Related]
15. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
Botana-Rial M; Casado-Rey P; Leiro-Fernández V; Andrade-Olivié M; Represas-Represas C; Fernández-Villar A
Clin Lab; 2011; 57(5-6):373-8. PubMed ID: 21755828
[TBL] [Abstract][Full Text] [Related]
16. Differentiating tuberculous from malignant pleural effusions: a scoring model.
Porcel JM; Vives M
Med Sci Monit; 2003 May; 9(5):CR175-80. PubMed ID: 12761453
[TBL] [Abstract][Full Text] [Related]
17. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
18. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
19. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
20. [Pleural effusions--experience of Pneumo-phtisiology Hospital Tudor Vladimirescu--I: Clinical study].
Olaru M; Pleşea IE; Mălăescu D; Olaru R
Pneumologia; 2008; 57(3):138-46. PubMed ID: 18998326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]